Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - Pernix Sleep, Inc. | c18711exv31w2.htm |
| EX-32.2 - EXHIBIT 32.2 - Pernix Sleep, Inc. | c18711exv32w2.htm |
| EX-31.1 - EXHIBIT 31.1 - Pernix Sleep, Inc. | c18711exv31w1.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Pernix Sleep, Inc. | Financial_Report.xls |
| 10-Q - FORM 10-Q - Pernix Sleep, Inc. | c18711e10vq.htm |
Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Certification of Chief Executive Officer
In connection with the Quarterly Report of Somaxon Pharmaceuticals, Inc. (the “Company”) on
Form 10-Q for the period ended June 30, 2011, as filed with the Securities and Exchange Commission
on the date hereof (the “Report”), I, Richard W. Pascoe, President and Chief Executive Officer of
the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that to my knowledge:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Dated: August 3, 2011 | /s/ Richard W. Pascoe | |||
| Richard W. Pascoe | ||||
| President and Chief Executive Officer | ||||
The foregoing certification is being furnished solely to accompany the Report pursuant to 18
U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of
1934, as amended, and is not to be incorporated by reference into any filing of the Company,
whether made before or after the date hereof, regardless of any general incorporation language in
such filing. A signed original of this written statement required by Section 906 has been provided
to the Company and will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.